Linking Persons With HIV, Discharged From Jail, With Community Care
Linking Persons With HIV, Discharged From Jail, With Community Care: a Direct Comparison of the Costs and Effects of Three HIV Management Strategies in the District of Columbia Department of Corrections
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Incarcerated Americans on any given day represent one in 40 (2.5%) Persons Living with HIV (PLWH) in this country, but those ever incarcerated over the course of a year represent 17% of the US epidemic. PLWH are a diverse group in terms of awareness and management of their disease. A portion may be aware of their HIV status and on treatment. This subgroup is at risk of disruption in care if incarcerated. Others may be aware of their status, but untreated, while still others may be unaware of their HIV status. The latter group is of particular importance in terms of the HIV epidemic in criminal justice settings, as a recent meta-analysis indicated that up to 15% of individuals entering jail have undiagnosed infections.
Good management of PLWH during a period of incarceration is critical. Ensuring that care relationships are maintained or newly established will improve health outcomes among PLWH and reduce the risk of transmission once they are discharged. As the median length of stay in jail is short (median < 7 days), rapid HIV testing is critical. Maximizing the yield and speed of HIV testing in a jail environment has the potential to promote rapid entry into care, or rapid re-engagement if persons have fallen out of care. For those testing negative, it can hasten the referral to Pre-Exposure Prophylaxis (PrEP) services.
How correctional facilities offer HIV testing and begin treatment affects long-term outcomes. Because of the rapid churn of jail, point-of-care (POC) rapid testing may lead to a higher percentage of patients receiving test results before leaving jail, compared to conventional assays. Fourth generation laboratory-based antigen/antibody (Ag/Ab) testing can diagnosis more persons with acute HIV infection, who may be in the window period before the POC test turns positive, but has a several hour test turn-around time, and those tested may leave jail before receiving their result. Using both tests for every entrant would permit the jail to experience the benefit of both methods but at greater expense. Collaborating with Washington, DC's city jail, known as DC Department of Corrections (DC DOC), and Unity Healthcare, the network of Federally Qualified Health Centers in Washington DC, which also provides care within the DC DOC, this study has a unique opportunity to measure rapidity of testing, linkage to and commencement of care, and achievement of viral suppression, along with costs of HIV identification.
This study uses a unique, time-sensitive opportunity to compare three separate strategies of universal HIV screening and treating. The strategies of POC testing, 4th generation laboratory-based Ag/Ab testing, and a combination of the two tests will be compared in the DC jail. A rigorous assessment of the three strategies in terms of their feasibility, process measures, and cost-effectiveness on an institutional level will help to guide implementation decisions in jails across the US.
One sub-study will assess the number of persons testing negative who are referred to prevention programs after leaving the jail. A second sub-study will examine antiviral use after jail release, among PLWH.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Contatti e Sedi
Luoghi di studio
-
-
District of Columbia
-
Washington, District of Columbia, Stati Uniti, 20009
- DC Department of Corrections
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria for Those Testing Negative for HIV:
- Able to understand and speak English
- Confirmed HIV negative status
- Planning to stay in the metropolitan DC area upon jail release
- Candidate for PrEP using attached screening instrument and interested in taking it
Inclusion Criteria for Those Testing Positive for HIV:
- Able to understand and speak English
- Confirmed HIV positive status
- Planning to stay in the metropolitan DC area upon jail release
Exclusion Criteria:
- none
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
POC Testing Alone
POC HIV testing (the current standard of care) will be conducted for persons entering jail during the first two-month period.
|
Point-of-care (POC) rapid HIV testing provides results within minutes, however, it cannot reliably detect new infections.
It can take up to 90 days after exposure for HIV infections to be diagnosed with POC rapid testing.
|
|
POC and 4th Generation Testing
POC plus 4th Generation HIV Testing will be conducted for persons entering jail during the second two-month period.
|
Point-of-care (POC) rapid HIV testing provides results within minutes, however, it cannot reliably detect new infections.
It can take up to 90 days after exposure for HIV infections to be diagnosed with POC rapid testing.
Fourth generation laboratory-based antigen/antibody (Ag/Ab) HIV testing can detect acute HIV infections (as early as 18 days after exposure), but it takes several hours to process.
|
|
4th Generation Testing Alone
4th Generation HIV Testing will be conducted for persons entering jail during the third two-month period.
|
Fourth generation laboratory-based antigen/antibody (Ag/Ab) HIV testing can detect acute HIV infections (as early as 18 days after exposure), but it takes several hours to process.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Entrants Tested
Lasso di tempo: Up to 24 hours
|
The number of entrants receiving an HIV test within 24 hours of intake will be examined.
|
Up to 24 hours
|
|
Percentage of PLWH Identified in First 24 Hours
Lasso di tempo: Up to 24 hours
|
The percentage of PLWH identified within the first 24 hours of admission, among all PLWH who enter, will be examined.
|
Up to 24 hours
|
|
Number of New HIV Diagnosed Prior to Discharge
Lasso di tempo: Up to Jail Discharge
|
The number of persons with a new diagnosis of HIV who receive test results before discharge will be examined.
|
Up to Jail Discharge
|
|
Number of Entrants with Acute HIV Infection Identified
Lasso di tempo: Up to 5 days
|
The number of entrants identified having an acute HIV infection will be examined.
|
Up to 5 days
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time Until Receipt of Positive Test Result
Lasso di tempo: Up to 5 days
|
The time (in hours) from the positive test result in persons not previously diagnosed and receipt of test report.
|
Up to 5 days
|
|
Time Until Receipt of Antiviral Dose
Lasso di tempo: Up to Jail Discharge
|
The time (in days) from entry until receipt of first dose of antiviral in the jail, for PLWH.
|
Up to Jail Discharge
|
|
Time Until Viral Suppression
Lasso di tempo: 6 months after positive HIV intake test
|
For all PLWH, the time (in days) from entry to achieving viral suppression, if not suppressed at baseline.
|
6 months after positive HIV intake test
|
|
Time Until Meeting with Discharge Planner
Lasso di tempo: Up to Jail Discharge
|
For all PLWH, the time (in days) from intake to meeting the discharge planner.
|
Up to Jail Discharge
|
|
Number of Participants Taking PrEP
Lasso di tempo: 2 months after jail release, 6 months after jail release
|
For those consenting to the first sub-study, the number of high-risk persons who test negative for HIV who successfully link to PrEP within 2 months of jail release and stay on PrEP for at least 6 months will be examined.
|
2 months after jail release, 6 months after jail release
|
|
Number of PLWH who Attend Clinic Visits
Lasso di tempo: 1 year
|
For persons living with HIV who consent to the second sub-study, the percentage of persons previously and newly diagnosed who make clinic visits at least once every 6 months will be examined.
|
1 year
|
|
Number of PLWH with Viral Suppression
Lasso di tempo: 6 months
|
For persons living with HIV who consent to the second sub-study, the percentage of persons previously and newly diagnosed who are virally suppressed 6 months after sub-study enrollment.
|
6 months
|
|
Cost of Each Testing Strategy
Lasso di tempo: 6 months
|
A cost-effectiveness analysis using the intermediate process measures will be conducted.
Units of resource items, such as tests and staff time, will be multiplied by their unit costs to calculate total costs.
Wage ranges provided by DOC and Unity Healthcare will be used to price staff time; market values will be used for all other items.
Costs will then be summed by testing strategy.
|
6 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Anne Spaulding, MD, MPH, Emory University
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Infezioni da virus a RNA
- Malattie virali
- Infezioni
- Infezioni a trasmissione ematica
- Malattie trasmissibili
- Malattie sessualmente trasmissibili, virali
- Malattie trasmesse sessualmente
- Infezioni da lentivirus
- Infezioni da retroviridae
- Sindromi da deficit immunologico
- Malattie del sistema immunitario
- Malattie da virus lenti
- Infezioni da HIV
- Sindrome da immunodeficienza acquisita
- Effetti fisiologici delle droghe
- Fattori immunologici
- Anticorpi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- IRB00115929
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Periodo di condivisione IPD
Criteri di accesso alla condivisione IPD
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .